DE60128893D1 - Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti-hsp antikörpern - Google Patents

Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti-hsp antikörpern

Info

Publication number
DE60128893D1
DE60128893D1 DE60128893T DE60128893T DE60128893D1 DE 60128893 D1 DE60128893 D1 DE 60128893D1 DE 60128893 T DE60128893 T DE 60128893T DE 60128893 T DE60128893 T DE 60128893T DE 60128893 D1 DE60128893 D1 DE 60128893D1
Authority
DE
Germany
Prior art keywords
treatment
pilzinfection
polyenes
synthesis inhibitors
beta glucan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60128893T
Other languages
English (en)
Other versions
DE60128893T2 (de
Inventor
James Peter Burnie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neutec Pharma Ltd
Original Assignee
Neutec Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Pharma Ltd filed Critical Neutec Pharma Ltd
Publication of DE60128893D1 publication Critical patent/DE60128893D1/de
Application granted granted Critical
Publication of DE60128893T2 publication Critical patent/DE60128893T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60128893T 2000-04-06 2001-03-20 Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti-hsp antikörpern Expired - Lifetime DE60128893T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0008305 2000-04-06
GBGB0008305.5A GB0008305D0 (en) 2000-04-06 2000-04-06 Treatment of fungal infections
PCT/GB2001/001195 WO2001076627A1 (en) 2000-04-06 2001-03-20 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies

Publications (2)

Publication Number Publication Date
DE60128893D1 true DE60128893D1 (de) 2007-07-26
DE60128893T2 DE60128893T2 (de) 2007-12-06

Family

ID=9889204

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60128893T Expired - Lifetime DE60128893T2 (de) 2000-04-06 2001-03-20 Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti-hsp antikörpern

Country Status (19)

Country Link
US (4) US20030180285A1 (de)
EP (4) EP1267925B8 (de)
JP (1) JP2003530357A (de)
CN (3) CN1420786A (de)
AT (1) ATE364396T1 (de)
AU (2) AU4089001A (de)
BR (1) BR0109846A (de)
CA (1) CA2401836A1 (de)
CY (1) CY1106794T1 (de)
DE (1) DE60128893T2 (de)
DK (1) DK1267925T3 (de)
ES (1) ES2287105T3 (de)
GB (1) GB0008305D0 (de)
NO (1) NO20024815L (de)
NZ (1) NZ520899A (de)
PL (1) PL358394A1 (de)
PT (1) PT1267925E (de)
RU (1) RU2262952C2 (de)
WO (1) WO2001076627A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050129665A1 (en) * 2002-07-25 2005-06-16 Martin Friedlander Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
US7651689B2 (en) * 2002-11-15 2010-01-26 Albert Einstein College Of Medicine Of Yeshiva University Methods of applying ionization radiation for therapy of infections
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
EP1457499A1 (de) * 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibitoren des extrazellulären Hitzeschockproteins Hsp90
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
GB0409077D0 (en) 2004-04-23 2004-05-26 Neutec Pharma Plc Treatment of fungal infections
CA2572318A1 (en) 2004-07-02 2006-01-12 Neutec Pharma Plc Treatment of cancer
JP2008504355A (ja) * 2004-07-02 2008-02-14 ニュウテック ファーマ リミテッド 癌の処置
EP2500031A3 (de) * 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Zusammensetzungen und Verfahren zur Behandlung von Gefäßpermeabilität
JP2008538750A (ja) * 2005-04-13 2008-11-06 アステックス、セラピューティックス、リミテッド 医薬化合物
GB0600168D0 (en) * 2006-01-05 2006-02-15 Neutec Pharma Plc A therapeutic composition
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
WO2008116216A1 (en) * 2007-03-22 2008-09-25 Medical College Of Georgia Research Institute, Inc. Compositions and methods for inhibiting cancer metastasis
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
WO2008132174A1 (en) * 2007-04-27 2008-11-06 Novartis Ag An immunoglobulin composition
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
CN111116743B (zh) * 2018-10-30 2022-01-28 迈威(上海)生物科技股份有限公司 Hsp90抗体及其在抗真菌感染中的应用
CN111679069A (zh) * 2019-12-31 2020-09-18 安徽中医药大学 一种通过耳道念珠菌细胞壁重构来评价中药单体抗真菌作用的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8915019D0 (en) * 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
GB2270076A (en) * 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
US6365165B1 (en) * 1995-09-22 2002-04-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6375955B1 (en) * 1995-09-22 2002-04-23 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US5834592A (en) * 1995-09-22 1998-11-10 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides

Also Published As

Publication number Publication date
US20080181884A1 (en) 2008-07-31
EP2011512A1 (de) 2009-01-07
JP2003530357A (ja) 2003-10-14
BR0109846A (pt) 2003-06-03
CA2401836A1 (en) 2001-10-18
RU2262952C2 (ru) 2005-10-27
CN101095952A (zh) 2008-01-02
CN1420786A (zh) 2003-05-28
CY1106794T1 (el) 2012-05-23
AU4089001A (en) 2001-10-23
ATE364396T1 (de) 2007-07-15
ES2287105T3 (es) 2007-12-16
WO2001076627A1 (en) 2001-10-18
DK1267925T3 (da) 2007-10-15
GB0008305D0 (en) 2000-05-24
AU2001240890B2 (en) 2005-06-16
WO2001076627A8 (en) 2001-11-15
EP1267925B8 (de) 2007-08-29
CN101683525A (zh) 2010-03-31
PT1267925E (pt) 2007-09-04
EP1818062A1 (de) 2007-08-15
DE60128893T2 (de) 2007-12-06
NZ520899A (en) 2005-03-24
US20100285029A1 (en) 2010-11-11
US20080193459A1 (en) 2008-08-14
US20030180285A1 (en) 2003-09-25
PL358394A1 (en) 2004-08-09
EP1852128A1 (de) 2007-11-07
NO20024815D0 (no) 2002-10-04
EP1267925A1 (de) 2003-01-02
RU2002129510A (ru) 2004-03-27
EP1267925B1 (de) 2007-06-13
EP1818062A3 (de) 2007-10-24
NO20024815L (no) 2002-12-02

Similar Documents

Publication Publication Date Title
DE60128893D1 (de) Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti-hsp antikörpern
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
CY1118053T1 (el) Φαρμακευτικες συνθεσεις με ανθεκτικοτητα σε διαλυτο cea
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
ATE414106T1 (de) Pegylierte single-domain-antikörper (dab)
NO20071436L (no) Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater
RS53752B1 (en) ANTITELO PROTIV ILT7
DK2316852T3 (da) Stabiliserede enkeltdomæne-antistoffer
DE60142342D1 (de) Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen
CO5160384A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que comprende el mismo
ATE482719T1 (de) Behandlungsverfahren unter verwendung von anti- cd22-antikörpern
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
EA200600275A1 (ru) Цитотоксический конъюгат, специфичный по отношению к са6 антигену, и способы его применения
GB2383331A (en) Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
ATE437186T1 (de) Anti-epcam-immunoglobuline
EP3300739A3 (de) An 161p2f10b-proteine bindende antikörper und zugehörige moleküle
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
BRPI0414513A (pt) kid3 e anticorpos de kid3 que se ligam a ele
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
ATE435032T1 (de) Impstoff gegen yersinia mit einem oder zwei monoklonaler antikörper, die für yersinia pestis f1-antigen und v-antigen spezifisch sind

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NEUTEC PHARMA LTD., CAMBERLEY, SURREY, GB

8364 No opposition during term of opposition